Idun Biologics ApS: Financial statements 2023
CVR: 43750380
Source: annual report 2023, Danish Business Authority
02/01/2023 – 31/12/2023
Idun Biologics ApS (CVR 43750380) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 662,220 and a net result of DKK -2,287. Equity in the 2023 report amounted to DKK 37,713. The solvency ratio was 32.2%.
- Gross Profit
- DKK 662,220
- Profit/Loss
- DKK -2,287
- Equity
- DKK 37,713
- Total Assets
- DKK 117,283
- Employees
- 0
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of January 2, 2023, Jens Frederik Teilfeldt Hansen is registered as director of Idun Biologics ApS.
As of January 2, 2023, Clarisse Eve Chiche-Lapierre is registered as director of Idun Biologics ApS.
As of January 2, 2023, Ymir Holdings ApS is registered as an owner of Idun Biologics ApS with an ownership share of 100%.
Idun Biologics ApS was founded on January 2, 2023.
About Idun Biologics ApS
Idun Biologics ApS is a Danish company of the type Anpartsselskab based in Aalborg, founded in 2023. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Clarisse Eve Chiche-Lapierre and Jens Frederik Teilfeldt Hansen. The company is owned by Ymir Holdings ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 475,329 and a net result of DKK -85,011 compared with DKK -192,043 the year before. Equity in the 2025 report amounted to DKK -239,341.
